摘要
目的探讨组蛋白乙酰化酶6(histonedeacetylases 6,HDAC6)选择性抑制剂23BB通过抑制人肾小管上皮细胞(HK-2)凋亡的肾脏保护机制。方法使用亚铁肌红蛋白诱导HK-2模拟横纹肌溶解致急性肾损伤的体外模型,将HK-2细胞分5组:空白对照组、亚铁肌红蛋白(myoglobin)组(200μM)、23BB治疗组(1.25nM)、4-PBA治疗组(2.0mM)及Tunicamycin刺激组(25ng/mL),采用逆转录-聚合酶链反应和蛋白质印迹法检测凋亡相关基因和蛋白情况。结果 Myoglobin诱导HK-2细胞模型中,23BB调控凋亡相关基因和蛋白表达。结论 HDAC6抑制剂23BB通过抑制肌红蛋白诱导HK-2细胞凋亡,达到急性肾损伤的保护作用
Objective To investigate the protective effects and mechanism of selective HDAC6 inhibitor 23 BB in myoglobin-induced proximal tubular cell lines(HK-2).Methods HK-2 cells were divided into control group,myoglobin(200μM)group,myoglobin+ 23 BB(1.25 nM)group,myoglobin+4-PBA(2 mM)group and myoglobin+23 BB+TM(25 ng/ml)group.Cells were collected at 24 hafter treatment.The apoptosis related gene mRNA level and marker protein expression were evaluated by RT-PCR and Western blotting.Results The apoptosis-related mRNA and marker protein expression were found to increase in response to myoglobin treatment.Conclusion The protective effect of HDAC6 inhibitor 23 BB was through the inhibition of myoglobin-induced apoptosis in HK-2 cells.
引文
[1] Bosch X,Poch E,Grau JM.Rhabdomyolysis and Acute KidneyInjury[J].New Eng J Med,2009,361(1):62-72.
[2] Raymond V,Sukriu SM,Ekrem E,et al.Rhabdomyolysis[J].J Amer Soc Nephrol,2000,11(8):1553-1561.
[3] Graham DJ,Staffa JA,Shatin D,et al.Incidence of hospital-ized rhabdomyolysis in patients treated with lipid-lowering drugs[J].JAM,2004,292(21):2585-2590.
[4] McMahon GM,Zeng X,Waikar SS.A risk prediction score forkidney failure or mortality in rhabdomyolysis[J].JAMA InternMed,2013,173(19):1821-1828.
[5] Petejova N,Martinek A.Acute kidney injury due to rhabdomy-olysis and renal replacement therapy:a critical review[J].Criti-cal Care,2014,18(3):224.
[6]张雪梅,唐怡,杨莹莹,等.肌红蛋白诱导的内质网应激及细胞凋亡在挤压综合征中的机制初探[J].四川大学学报(医学版),2014,46(1):22-26.
[7] Liuqing X,Jinhua T,Lu F,et al.Inhibition of HDAC6pro-tects against rhabdomyolysis-induced acute kidney injury[J].AJP-Renal Physiol,2017,312(3):502-515.
[8] Tang J,Yan Y,Zhao TC,et al.Class I HDAC activity is re-quired for renal protection and regeneration after acute kidneyinjury[J].AJP-Renal Physiol,2014,307(3):303-316.
[9] Yang Z,Wang T,Wang F,et al.Discovery of Selective His-tone Deacetylase 6Inhibitors Using the Quinazoline as the Capfor the Treatment of Cancer[J].J Med Chem,2016,59(4):1455-1470.
[10] Feng Y,Huang R,Guo F,et al.Selective Histone Deacetylase6Inhibitor 23BB Alleviated Rhabdomyolysis-Induced Acute Kid-ney Injury by Regulating Endoplasmic Reticulum Stress and Ap-optosis[J].Front Pharmacol,2018,9:274.
[11] Huang R,Zhou J,Feng Y,et al.Pharmacological Inhibition ofMacrophage Toll-like Receptor 4/Nuclear Factor-kappa B Alle-viates Rhabdomyolysis induced Acute Kidney Injury[J].Chin JMed,2017,130(18):2163-2169.
[12] Fan Y,Xiao W,Li,et al.RTN1mediates progression of kid-ney disease by inducing ER stress[J].Nat Comm,2015,6:7841.
[13] Huerta-Alardín AL,Varon J,Marik PE.Bench-to-bedside re-view:Rhabdomyolysis-an overview for clinicians[J].CriticalCare,2004,9(2):158.
[14] Holt S,Moore K.Pathogenesis of renal failure in rhabdomyoly-sis:the role of myoglobin[J].Exp Nephrol,2000,8(2):72-76.
[15] Boutaud O,Roberts L.Mechanism-based therapeutic approa-ches to rhabdomyolysis-induced renal failure[J].Free Radic BiolMed,2011,51(5):1062-1067.
[16] Panizo N,Rubio-Navarro A,Amaro-Villalobos JM,Egido J,etal.Molecular Mechanisms and Novel Therapeutic Approachesto Rhabdomyolysis-Induced Acute Kidney Injury[J].KidneyBlood Pressure Res,2015,40(5):520-532.
[17] Zhou J,Kong D,Zhang X,et al.Myoglobin-induced apoptosis:two pathways related to endoplasmic reticulum stress[J].TherApher Dial,2012,16(3):272-280.
[18] Hubbert C,Guardiola A,Shao R,et al.HDAC6is a microtu-bule-associated deacetylase[J].Nature,2002,417(6887):455-458.
[19] Taniguchi M,Yoshida H.Endoplasmic reticulum stress in kid-ney function and diseasep[J].Curr Opin Nephrol Hypertens,2015,24(4):345-350.
[20] Tábara L,Poveda J,Martin-Cleary C,et al.Mitochondria-tar-geted therapies for acute kidney injury[J].Expert Rev MolMed,2014,16:13.
[21] Cunard R.Endoplasmic Reticulum Stress in the Diabetic Kid-ney,the Good,the Bad and the Ugly[J].J Clin Med,2015,4(4):715-740.
